Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Investing.com - Citizens JMP has reiterated its Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ:KURA) following the company’s investor event showcasing preclinical data for KO-2806, its next-generation farnesyl transferase inhibitor. According to InvestingPro data, analysts’ targets range from $11 to $40, with the stock currently appearing undervalued based on Fair Value analysis.
The preclinical data highlighted KO-2806’s ability to overcome resistance to targeted therapies by suppressing mTORC1 signaling, with consistent synergy observed across VEGF, PI3Kα, and pan-RAS inhibitors. Enhanced anti-tumor activity was demonstrated in preclinical models of RCC, NSCLC, CRC, and PIK3CA-mutant HNSCC, supporting the compound’s potential as a broadly applicable combination agent.
Clinical findings for KO-2806 will be presented at the ESMO conference, scheduled for October 17-21, 2025. The company’s lead drug candidate, zifto, remains on track for potential approval with a PDUFA date of November 30, 2025.
Kura Oncology plans to initiate front-line trials in the second half of 2025, which are fully funded according to Citizens JMP. The company maintains a strong financial position with $630.7 million in cash.
Citizens JMP noted that Kura shares currently trade at an enterprise value of $103.6 million as the company approaches commercialization of its first drug.
In other recent news, Kura Oncology reported its second-quarter 2025 financial results, revealing a significant shortfall in revenue expectations. The company posted $15.3 million in revenue, falling short of the forecasted $39.1 million, marking a 60.88% discrepancy. Additionally, Kura reported a loss of $0.75 per share, which was below the anticipated loss of $0.41. In terms of analyst coverage, Citizens JMP adjusted its price target for Kura Oncology to $24 from $28, although it maintained a Market Outperform rating, signaling continued confidence in the company’s outlook. Guggenheim initiated coverage on Kura with a Neutral rating, noting challenges in the upcoming launch of ziftomenib in the AML market due to existing competition. Meanwhile, Kura is set to present preliminary data on its cancer drug darlifarnib at the European Society of Medical Oncology Congress in October 2025. The company highlighted preclinical research suggesting darlifarnib might enhance the effectiveness of targeted cancer therapies. These recent developments reflect ongoing strategic and competitive dynamics for Kura Oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.